New Personalized Genetic Test- ProstaVysionTM- Helps Prostate Cancer Patients Make Best Treatment Decisions

Test Defines the Aggressiveness of Prostate Cancer

RICHMOND, Va.--(BUSINESS WIRE)-- Treatment of prostate cancer is often confusing for patients, but ProstaVysion™ – the first personalized genetic panel for prostate cancer – optimizes that choice by defining the aggressiveness of the cancer.

Exclusively from Bostwick Laboratories® and available immediately, ProstaVysionTM examines the genetic status of that patient’s prostate cancer. This personalized analysis gives the patient and his physician the genetic information needed to make the best treatment decision. Even more important, the test can provide peace of mind for patients who are considering active surveillance rather than definitive therapy at diagnosis.

ProstaVysionTM examines three important genetic markers linked to prostate cancer, including DNA methylation of HOXD3, gene fusion/translocation analysis of ERG protein, and loss of the tumor suppressor gene PTEN. Triple-positive results with these markers indicate a poor long-term prognosis, while triple-negative results indicate a favorable prognosis; this is important and actionable information for treatment choices.

J. Maxwell White, M.D. of Peachtree Urology in Atlanta states, “The recent addition of HOXD3, ERG, and PTEN has allowed a significant refinement in the assessment of patients with prostate cancer beyond Gleason scoring, particularly in those patients with intermediate risk cancer.”

“We believe that ProstaVysionTM successfully addresses the significant unmet need of defining how aggressive a specific prostate cancer is, empowering the patient and his physician to make the best possible treatment decision,” said David G. Bostwick MD, MBA, Chief Medical Officer of Bostwick Laboratories. “If the cancer is triple-positive, definitive therapy is probably preferred; if the cancer is triple-negative, then more conservative therapy may be a consideration.”

About Bostwick Laboratories

Bostwick Laboratories is the leading full-service medical laboratory in urologic pathology, featuring a veteran staff of board-certified, internationally renowned pathologists dedicated to the diagnosis, treatment and subsequent management of prostate cancer and all urologic conditions. For more information, visit our website at


Bostwick Laboratories
Brent Sower, Executive Vice President of Marketing, 804-967-9225
Fax: 804-239-1991
[email protected]

KEYWORDS:   United States  North America  Virginia

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Radiology  Research  Consumer  Science  Men